Memantine Hydrochloride Extended-Release Capsules, 28 mg, 100 capsules per unit dose cartons, Rx ...
FDA Drug Recall #D-1262-2020 — Class III — April 24, 2020
Recall Summary
| Recall Number | D-1262-2020 |
| Classification | Class III — Low risk |
| Date Initiated | April 24, 2020 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | The Harvard Drug Group |
| Location | Livonia, MI |
| Product Type | Drugs |
| Quantity | 678 cartons |
Product Description
Memantine Hydrochloride Extended-Release Capsules, 28 mg, 100 capsules per unit dose cartons, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.)-454 775, India; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 47152 USA. NDC: 0904-6735-61
Reason for Recall
Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing.
Distribution Pattern
AL, FL, IA, NY, OH, TX
Lot / Code Information
Lot #: M02199D, M02246D, Exp 5/2020
Other Recalls from The Harvard Drug Group
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0878-2023 | Class II | Tramadol Hydrochloride Tablets, USP 50 mg, Unit... | Jun 16, 2023 |
| D-0570-2023 | Class III | Gabapentin Tablets, USP 600 mg, packaged in Car... | Apr 24, 2023 |
| D-0432-2023 | Class II | Carbidopa and Levodopa Tablets, USP 25 mg/100 m... | Feb 23, 2023 |
| D-0649-2022 | Class II | PALIPERIDONE EXTENDED-RELEASE TABLETS, 9 mg, 10... | Feb 28, 2022 |
| D-0653-2022 | Class II | hydrALAZINE HCl Tablets, USP, 10 mg, 100 Tablet... | Feb 24, 2022 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.